Logo for Respiratorius

Respiratorius Investor Relations Material

Latest events

Logo for Respiratorius

Q1 2024

21 May, 2024
Logo for Respiratorius

Q4 2023

13 Feb, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Respiratorius

Access all reports
Respiratorius AB develops drug candidates with the goal of launching or out-licensing drugs for the treatment of aggressive lymphoma (cancer). Respiratorius is developing a new drug as a pretreatment to enhance the effects of the standard treatment currently used for the treatment of diffuse large B-cell lymphoma, the most common type of aggressive lymphoma.